{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-132301","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2025-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.282936+00:00","generated_at":"2026-05-20T04:13:04.409603+00:00","sec_items":["5.02","5.07","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fate Therapeutics appoints Matthew Abernethy to board; shareholders boost authorized shares to 350M","bullets":["Matthew Abernethy, CFO of Neurocrine Biosciences, appointed Class III director; Timothy P. Coughlin steps down.","Stockholders approved increase in authorized common shares from 250M to 350M, effective May 29, 2025.","Second amendment to 2022 stock plan approved, adding 7M shares to the reserve.","Dr. Shefali Agarwal and Dr. Bahram Valamehr re-elected Class III directors; E&Y ratified as auditor.","Non-binding say-on-pay passed with ~68.9M for (92.4% of votes cast); frequency set at 1 year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-132301","json":"https://secwatch.observer/filing/0001193125-25-132301.json","markdown":"https://secwatch.observer/filing/0001193125-25-132301.md","text":"https://secwatch.observer/filing/0001193125-25-132301.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/0001193125-25-132301-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/d42374d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T04:13:04.409603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66dc32bd52","claim":"Timothy P. Coughlin departed as Director at FATE THERAPEUTICS INC.","evidence_excerpt":"Concurrently with Mr. Abernethy’s election at the Annual Meeting, Timothy P. Coughlin’s term as a member of the Board and the Audit Committee thereof ended.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/0001193125-25-132301-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"term ended"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c4df511090","claim":"Matthew Abernethy was appointed as Class III Director at FATE THERAPEUTICS INC.","evidence_excerpt":"appointed Matthew Abernethy to the Board to serve as a Class III director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/0001193125-25-132301-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"5f0bdf2cc1371eb88020b4d6e61d55a02f259685","claim":"FATE THERAPEUTICS INC: Increased authorized shares of Common Stock from 250,000,000 to 350,000,000 (effective 2025-05-29).","evidence_excerpt":"to increase the number of authorized shares of Common Stock from 250,000,000 shares to 350,000,000 shares","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/0001193125-25-132301-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-05-29"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}